[5]. Estrada RA, Maselli DJ, Anzueto AR. In COPD with type 2 inflammation despite inhaled triple therapy, dupilumab safely reduced exacerbations[J]. Ann Intern Med. 2023 Sep;176(9):JC102. [6]. 汪雅婷,梁瀛. 嗜酸粒细胞增多表型慢性阻塞性肺疾病的临床研究进展[J]. 国际呼吸杂志,2022,42(14)...
[5]. Estrada RA, Maselli DJ, Anzueto AR. In COPD with type 2 inflammation despite inhaled triple therapy, dupilumab safely reduced exacerbations[J]. Ann Intern Med. 2023 Sep;176(9):JC102. [6]. 汪雅婷,梁瀛. 嗜酸粒细胞增多表型慢性阻塞性肺疾病的临床研究进展[J]. 国际呼吸杂志,2022,42(14)...
7. 中华医学会呼吸病学分会慢性阻塞性肺疾病学组 , 中国医师协会呼吸医 师分会慢性阻塞性肺疾病工作委员会 . 慢性阻塞性肺疾病急性加重高风 险患者识别与管理中国专家共识[J]. 国际呼吸杂志,2022,42(24):1845 - 1863. 8.Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with Type 2 Inflam...
for COPD in targeted populations,the update of blood eosinophil count,the update of interstitial lung abnormalities,the revision of the section on smoking cessation,the update of vaccination recommendations for people with COPD,the expansion of managing inhaled therapy,and the addition of pharmacotherapie...
GOLD指南:COPD管理的“风向标”GOLD(慢性阻塞性肺疾病全球创议)始于1998年,在美国国立心肺和血液研究院、NIH和WHO的合作下,,依据循证医学,于2001年首次发布COPD全球策略(指南)2003年至2010年,GOLD每年发布更新指南,2011年11月APSR会议上公布了最新版GOLD指南更新解析全文共37页,当前为第1页。
exacerbationsor 21leadingto hospitalization 0or1moderate exacerbations (notleadingto hospitalization) mMRC0-1CAT10 GRADE GOLD1 GOLD2 Assessmentof airflowobstruction Spirometrically confirmeddiagnosis Post-bronchodilatorFEV1/FVC0.7 GOLD3 GOLD4 30-49
Assessment Using Symptoms, Breathlessness, Spirometric Classification, and Risk of Exacerbations 15viiTable 5.8. Indications for Invasiv 54、e Mechanical Ventilation 44Table 5.9. Discharge Criteria 44 Table 5.10. Checklist of items to assess at time ofDischarge from Hospital 44 Table 5.11. Items to ...
1.GOLD2014.2.GroenewegenKH,etal.Mortalityandmortality-relatedfactorsafterhospitalizationforacuteexacerbationofCOPD.Chest,2003,124(2):459-467.长期使用全身激素是COPD患者死亡风险增加的独立危险因素2REDUCE研究:短期vs.传统激素治疗多中心,双盲,随机AECOPD患者(N=314)Day1甲强龙40mgivDay2~5泼尼松40mg/dDay1甲强...
GOLD classification of COPD: discordance in criteria for symptoms and exacerbation risk assessment. COPD. 2017; 14(1):1-6.Mittal R, Chhabra SK.GOLD classification of COPD: discordance in criteria for symptoms and exacerbation risk assessment [J]. COPD, 2017,14:1-6....
吸入激素使COPD急性加重减少24%(95%CI,20%-28%)。 In6placebo-controlledtrials(1741patients)withatleasta6-monthfollow-upperiod,inhaledcorticosteroidsledtoa24%reductioninCOPDexacerbations(95%CI,20%-28%).;对9个随机、安慰剂对照,4198例患者,随访期至少3个月,观察LABA预防COPD急性加重作用的临床试验进行meta分...